PARIS, Nov 04, 2009 (BUSINESS WIRE) -- Regulatory News:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and
supportive care of cancer and AIDS patients, has presented results on miconazole
Lauriad(R) at the 47th Annual Meeting of the Infectious Diseases Society of
America (IDSA) in Philadelphia (October 29 -- November 1st).
The additional results from BioAlliance Pharma's pivotal Phase III study with
miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) demonstrated comparable
efficacy and safety profile to that of clotrimazole troches (administered five
times per day) for oropharyngeal candidiasis (OPC), in HIV-positive patients in
40 sites in the United States, Canada and South Africa. The data also
demonstrated a good patient compliance as a result of the added convenience of a
once-a-day dosing.
This presentation was given by Dr Rajesh V. Lalla, oral medicine specialist,
from the University of Connecticut Health Center.
OPC, also known as thrush, is an oral fungal infection most common in
individuals with weakened immune systems -- particularly those with HIV/AIDS and
those undergoing cancer treatments. OPC is a disruptive condition that results
in lesions and inflammation in the mouth, and includes symptoms such as
soreness, burning and/or altered taste.
About IDSA
The Infectious Diseases Society of America (IDSA) represents physicians,
scientists and other health care professionals who specialize in infectious
diseases. IDSA's purpose is to improve the health of individuals, communities,
and society by promoting excellence in patient care, education, research, public
health, and prevention relating to infectious diseases.
About BioAlliance Pharma
As a preferred partner for hospital-based specialists, BioAlliance Pharma is a
company which develops and markets innovative products in France, especially in
the fields of opportunistic infections and chemotherapy complications. In areas
where medical needs are insufficiently met, our targeted approaches help
overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma's ambition is to become a leading player in these fields by
coupling innovation to patient needs.
For more information, visit the BioAlliance Pharma web site at
http://www.bioalliancepharma.com.
Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning BioAlliance Pharma SA and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors, which
could cause the actual results, financial condition, performance or achievements
of BioAlliance Pharma SA to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking
statements. BioAlliance Pharma SA is providing this communication as of this
date and does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results,
financial condition, performance or achievements of BioAlliance Pharma SA to
differ from those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document
filed with the AMF on April 7, 2009, which is available on the AMF website
(http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website
(http://www.bioalliancepharma.com).
SOURCE: BioAlliance Pharma
CONTACT:
BioAlliance Pharma SA
Dominique Costantini MD, President and CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com
or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com
